Answers are grounded in this paper and cite their sources.
Inflammatory bowel disease (IBD) is a chronic relapsing disorder with increasing global prevalence and persistent therapeutic challenges. Marine sulfated polysaccharides (MSPs) have attracted growing interest because of their structural diversity and broad intestinal bioactivities. This review summarizes current evidence that MSPs alleviate experimental colitis by modulating inflammation and immune responses, strengthening epithelial and mucus barriers, reducing oxidative stress, and reshaping the gut microbiota. Particular emphasis is placed on structure-dependent microbiota–metabolite–host interactions, including short-chain fatty acids, bile acid metabolism, and tryptophan-derived signaling. Molecular weight, monosaccharide composition, glycosidic linkages, branching, and sulfation collectively influence MSP bioactivity. Despite promising preclinical findings, translation is limited by structural heterogeneity, inconsistent characterization, and insufficient mechanistic and clinical validation. Standardized structural analysis and well-designed mechanistic and clinical studies are therefore essential to establish reproducible structure-function relationships and therapeutic relevance in IBD.
No takes yet. Share an insight, caveat, or question.
Luo et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: